BALTIMORE--(BUSINESS WIRE)--AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing vital new therapies based on a novel peptide platform, today announced that it has raised $5 million in Convertible Note funding, led by Barer & Son Capital with additional funds from Rapha Capital Management, Salem Partners, TEDCO, and Piedmont Capital Partners. In concert with the funding, AsclepiX expanded its board to add Josh Barer, Kevin Slawin, MD, and Sapna Srivastava, PhD, to the founding members Aleksander Popel, PhD and Jordan J. Green, PhD and CEO Wendy Perrow, MBA.

Synteract has snapped up specialty contract researcher Cu-Tech, with plans to establish a dedicated center for the development of dermatology products and make the midsized, global CRO into a destination for skin-care clinical trials.

Mountain Lakes, New Jersey-based Cu-Tech has managed more than 130 dermatology trials over the past two decades, covering a variety of indications. The financial details of the acquisition were not disclosed.

OncoNano, a cancer diagnostics and therapeutics company, secured $11.7 million in Series A financing led by 3M New Ventures, LLC, with participation from CPRIT and other investors. This funding will propel their novel platform technology and lead product candidates toward clinical trials. OncoNano's approach focuses on developing molecules that activate specifically within the tumor microenvironment for targeted diagnostic and therapeutic applications, advancing their mission to improve cancer diagnosis and treatment.

ATLANTA, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Femasys Inc., a developer of innovative medical devices for the women's healthcare market, today announced that it has closed $40 million in Series C financing.  The transaction was arranged by Salem Partners, a Los Angeles-based investment bank which also participated as a principal investor. The Series C syndicate included multiple institutional investors, family offices and a multibillion-dollar global medical device company. The funding will be used primarily to support the pivotal testing of FemBloc™, the Company’s revolutionary, non-surgical permanent contraception solution. Femasys designed FemBloc to provide women with the first non-surgical permanent contraceptive option delivered exclusively in the physician’s office.

COPPELL, Texas--(BUSINESS WIRE)--ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular, and liver disorders, today announced that it has completed a $55 million Series D financing. The investor syndicate was led by Novo A/S and included new investors RA Capital, Adage Capital, Sofinnova Ventures, and one other top-tier institutional investor. The financing also included existing investors Alta Partners, Devon Park Bioventures, 3x5 Special Opportunity Fund, Salem Partners and RiverVest. Proceeds will be used to advance development of ZS-9, the Company’s lead product candidate for the treatment of hyperkalemia, through its New Drug Application (NDA) and Marketing Authorization Application (MAA) submissions in early 2015.

October 23, 2012 - Specialty pharmaceutical company ZS Pharma, Inc. has raised $46 million to advancedevelopment of ZS-9, a crystal form of zirconium silicate, designed to treat patients with kidney and liver disease.Alta Partners led the new round of financing, joined by new investors RiverVest Venture Partners, 3x5 Special Opportunity Partners and Salem Partners as well as current investor Devon Park Bioventures. The funding will allow ZS Pharma to proceed with pivotal trials for ZS-9 as it prepares for commercialization of the product.

‍